文献速递介入技术与安全CTMR

CT引导经皮射频消融治疗寡转移淋巴结的可行性与安全性

Feasibility and safety of percutaneous computed tomography guided radiofrequency ablation of lymph nodes in oligometastatic patients: a single center's experience.
PubMed 文献 · Br J Radiol · 2021-03-23

单中心回顾性研究纳入16例患者24枚转移性淋巴结,行CT引导经皮射频消融,平均大小1.78±0.83 cm,按mRECIST完全缓解率75%(18/24),再次消融后达87.5%(21/24),并发症率低,结论为安全可行。

要点

  • CT引导经皮RFA可用于寡转移淋巴结的局部控制,完全缓解率75%。
  • 对未完全缓解病灶可再次RFA,完全缓解率提升至87.5%。
  • 并发症率低,但需注意术后随访评估局部肿瘤控制。

核心结论

  • CT引导经皮RFA治疗寡转移性淋巴结安全可行,可实现较高的局部肿瘤控制。

研究设计与样本

  • 单中心回顾性研究,纳入16例患者共24枚转移性淋巴结,接受CT引导经皮射频消融。
  • 采用增强CT或MRI进行消融后随访,评估技术成功、临床成功及并发症率。

诊断标准与关键数值

  • 按mRECIST标准评估,消融后总体完全缓解率为75%(18/24可评估肿瘤)。
  • 对2例患者3枚病灶再次RFA后,完全缓解率升至87.5%(21/24可评估肿瘤)。

临床应用与阅片要点

  • CT引导经皮RFA可作为寡转移淋巴结的局部治疗选择,报告时应描述消融范围及随访影像的完全缓解评估。

局限性

  • 单中心回顾性设计,样本量小(16例患者24枚淋巴结),随访时间有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To retrospectively evaluate feasibility and safety of CT-guided percutaneous radiofrequency ablation (RFA) of metastatic lymph nodes (LN) in terms of achieving local tumor control.

METHODS: Institutional database research identified 16 patients with 24 metastatic LNs who underwent percutaneous CT-guided radiofrequency ablation. Mean patient age was 66.6 ± 15.70 years (range 40-87) and male/female ratio was 8/8. Contrast-enhanced CT or MRI was used for post-ablation follow-up. Patient and tumor characteristics and RFA technique were evaluated. Technical and clinical success on per tumor and per patient basis as well as complication rates were recorded.

RESULTS: Mean size of the treated nodes was 1.78 ± 0.83 cm. The mean number of tumors per patient was 1.5 ± 0.63. The mean procedure time was 56.29 ± 24.27 min including local anesthesia, electrode(s) placement, ablation and post-procedural CT evaluation. Median length of hospital stay was 1.13 ± 0.34 days. On a per lesion basis, the overall complete response post-ablation according to the mRECIST criteria applied was 75% (18/24) of evaluable tumors. Repeat treatment of an index tumor was performed on two patients (three lesions) with complete response achieved in 87.5% (21/24) of evaluable tumors following a second RFA. On a per patient basis, disease progression was noted in 10/16 patients at a mean of 13.9 ± 6.03 months post the ablation procedure.

CONCLUSION: CT-guided percutaneous RFA for oligometastatic LNs is a safe and feasible therapy.

ADVANCES IN KNOWLEDGE: With this percutaneous therapeutic option, metastatic LNs can be eradicated with a very low complication rate.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Filippiadis D, Charalampopoulos G, Tsochatzis A, et al. Feasibility and safety of percutaneous computed tomography guided radiofrequency ablation of lymph nodes in oligometastatic patients: a single center's experience. Br J Radiol. 2021. PMID: 33756082. doi:10.1259/bjr.20200445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。